Skip to main content

Recent News & Research

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer Research

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several studies suggest that antibiotic use (which alters the gut microbiome) may…
laurabbook@gmail.com
August 12, 2019
EGFR Resisters logo
Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow ResearchTreatments

Video: Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow

The EGFR Resisters hosted Dr. Josh Bauml for an extremely informative Facebook Live presentation on "Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & Tomorrow. https://www.youtube.com/watch?v=GRVMj_AbVOs&feature=youtu.be
laurabbook@gmail.com
July 6, 2019
1st Annual EGFR Resisters Research Summit – November 15-16, 2019 in Chicago Research

1st Annual EGFR Resisters Research Summit – November 15-16, 2019 in Chicago

We are very excited to announce that the EGFR Resisters will be holding our first Research Summit in collaboration with CEC Oncology, thanks to an independent educational grant from AstraZeneca. We are currently inviting Young Investigators (Junior Faculty or Fellows) in the EGFR lung cancer space to submit abstracts to…
laurabbook@gmail.com
July 6, 2019
Warning: Using Osimertinib After Immunotherapy ResearchTreatments

Warning: Using Osimertinib After Immunotherapy

*June 2019*  Medscape.  The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events) in some advanced lung cancer patients. Medscape (3/20, Castellino, Subscription Publication) reports a study team “notes that serious iirAEs were seen when osimertinib was given after immunotherapy in six of 41…
laurabbook@gmail.com
June 18, 2019
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients ResearchTreatments

High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients

*January 2019*  Lung Cancer.   This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma. (By treatment naïve, these patients had not received any other treatments first such as conventional chemo. By…
laurabbook@gmail.com
June 18, 2019
Deep Dive: Brigatinib + Cetuximab Combo for Triple-Mutant EGFR ResearchTreatments

Deep Dive: Brigatinib + Cetuximab Combo for Triple-Mutant EGFR

*March 2019*  Overview written by Donald Ox. This article deals with a case study of the latest clinical data of brigatinib + cetuximab combo that has stabilized a triple-mutant EGFR patient with concomitant EGFR-T790M and C797S mutations.  Brigatinib, the dual EGFR-ALK inhibitor, especially when used in combination of with anti-EGFR…
laurabbook@gmail.com
March 17, 2019